期刊文献+

滑石粉分散片的制备及处方优化 被引量:3

Preparation and Prescription Optimization of Talci Pulvis Dispersible Tablets
原文传递
导出
摘要 目的:制备滑石粉分散片并优选其处方工艺。方法:以崩解时限、分散均匀性或软材成型情况为指标,通过单因素试验筛选滑石粉分散片的辅料种类;选取滑石粉、崩解剂、填充剂用量为考察因素,以崩解时限、分散均匀性和混悬稳定性为综合评价指标,采用综合评分法和D-最优混料设计优选滑石粉分散片处方。结果:最佳制备工艺为以微晶纤维素为填充剂,含羟丙基甲基纤维素(HPMC)的30%乙醇溶液为黏合剂,交联聚乙烯吡咯烷酮(PVPP)为崩解剂,最优处方比例为滑石粉-微晶纤维素-PVPP(0.447∶0.400∶0.123)。结论:优选的制备工艺稳定可行;D-最优混料设计可用于滑石粉分散片处方的优化,建立的数学模型具有良好预测性。 Objective: To prepare Talci Pulvis dispersible tablets and optimized its prescription process. Method: Wtih disintegration time,dispersible uniformity or soft material molding conditions as indexes,excipients species of Talci Pulvis dispersible tablets were screened by single factor tests;With the amount of Talci Pulvis,disintegrating agents and stuffing bulking agents as factors,comprehensive scoring method and D-optimal mixture design were adopted to optimize prescription of Talci Pulvis dispersible tablets by taking disintegration time,dispersible uniformity and suspension stability as indicators. Result: Optimal preparation technology was as following:with microcrystalline cellulose(MCC) as a filler,30% ethanol configured hydroxy propyl methyl cellulose(HPMC) as a binder,cross-linked polyvinylpyrrolidone(PVPP) as a disintegrating agent;The best proportion of prescriptions was Talci Pulvis-MCC-PVPP (0.447:0.400:0.123). Conclusion: Optimized preparation tehcnology was stable and feasible; Established mathematical model of D-optimal mixture design had good predictability which could be used to optimize prescription of Talci Pulvis dispersible tablets.
出处 《中国实验方剂学杂志》 CAS 北大核心 2013年第24期13-16,共4页 Chinese Journal of Experimental Traditional Medical Formulae
基金 国家中医药管理局项目(201007011-09)
关键词 滑石粉 分散片 单因素试验 综合评分法 D-最优混料设计 Talci Pulvis dispersible tablets single factor test comprehensive evaluation method D-optimal mixture design
  • 相关文献

参考文献8

二级参考文献21

  • 1王鹏,王玉珠,沈建民.均匀设计及其在药学中的应用[J].沈阳药学院学报,1989,6(4):297-305. 被引量:74
  • 2王剑红,陆彬,胥佩菱,包定元,张自然.肺靶向米托蒽醌明胶微球的研究[J].药学学报,1995,30(7):549-555. 被引量:25
  • 3国家药典委员编.中华人民共和国药典[S].一部,北京:化学工业出版社,2005:362.
  • 4刘玉雯,余祥彬,吴宏霞.酮洛芬羟丙基-β-环糊精分散片的处方研究和溶出度考察[J].中国新药杂志,2007,16(15):1191-1194. 被引量:4
  • 5奚念朱,药剂学(第2版),1989年
  • 6Wang Y M,J Pharm Sci,1996年,85卷,11期,1204页
  • 7黄晓川.黄芪分散片[P].中国专利:CN200910216486.1.
  • 8G.阿尔德勒,C.尼斯特伦.药物粉体压缩技术[M].北京:化学工业出版社,2008:4.
  • 9Sébastien Branchu,Robert T. Forbes,Peter York,H?kan Nyqvist. A Central Composite Design to Investigate the Thermal Stabilization of Lysozyme[J] 1999,Pharmaceutical Research(5):702~708
  • 10Emad Eldin Hassan,Roy C. Parish,James M. Gallo. Optimized Formulation of Magnetic Chitosan Microspheres Containing the Anticancer Agent, Oxantrazole[J] 1992,Pharmaceutical Research(3):390~397

共引文献891

同被引文献26

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部